# Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)

> **NCT01736475** · PHASE2,PHASE3 · COMPLETED · sponsor: **Baxalta now part of Shire** · enrollment: 159 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **BIOLOGICAL:** Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
- **BIOLOGICAL:** PEGylated Recombinant Factor VIII
- **BIOLOGICAL:** PEGylated Recombinant Factor VIII
- **BIOLOGICAL:** PEGylated Recombinant Factor VIII

## Key facts

- **NCT ID:** NCT01736475
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01-31
- **Primary completion:** 2014-07-17
- **Final completion:** 2014-07-17
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2021-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01736475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01736475, "Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)". Retrieved via AI Analytics 2026-08-20 from https://api.ai-analytics.org/clinical/NCT01736475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*